← Back to headlines
Kiniksa Pharmaceuticals Forecasts $900M–$920M ARCALYST Revenue for 2026
Kiniksa Pharmaceuticals has provided guidance for its ARCALYST revenue in 2026, expecting it to be between $900 million and $920 million as the company deepens its market penetration.
24 Feb, 16:19 — 24 Feb, 16:19
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Prudential Bank, Mastercard discuss support for SMEs and corporates
13m ago
Workday Stock Dives on Earnings and AI Investment Costs
18m ago
Tigo Energy outlines 26%–30% revenue growth target for 2026 amid U.S. manufacturing expansion and new product launches
18m ago
Matson Forecasts Strong 2026 Operating Income Amid Southeast Asia Expansion
18m ago